Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.14% | 29.32% | 32.00% | 37.64% | -0.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.14% | 29.32% | 32.00% | 37.64% | -0.70% |
| Cost of Revenue | 54.63% | 42.51% | 26.72% | 26.47% | 37.28% |
| Gross Profit | -59.09% | -44.88% | -25.74% | -23.97% | -47.56% |
| SG&A Expenses | 74.36% | 67.19% | 60.86% | 30.25% | 34.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.12% | 49.53% | 36.31% | 27.53% | 36.55% |
| Operating Income | -63.87% | -52.00% | -36.86% | -26.01% | -43.28% |
| Income Before Tax | -70.69% | -60.27% | -39.94% | -30.89% | -46.27% |
| Income Tax Expenses | 100.30% | 89.53% | 72.23% | -- | -- |
| Earnings from Continuing Operations | -73.14% | -62.31% | -41.33% | -29.12% | -44.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.14% | -62.31% | -41.33% | -29.12% | -44.21% |
| EBIT | -63.87% | -52.00% | -36.86% | -26.01% | -43.28% |
| EBITDA | -60.65% | -50.34% | -35.91% | -24.03% | -39.72% |
| EPS Basic | -8.88% | -9.78% | -5.65% | -5.48% | -18.89% |
| Normalized Basic EPS | -6.99% | -8.13% | -4.81% | -6.76% | -20.19% |
| EPS Diluted | -9.09% | -10.00% | -5.88% | -5.53% | -18.89% |
| Normalized Diluted EPS | -6.99% | -8.13% | -4.81% | -6.76% | -20.19% |
| Average Basic Shares Outstanding | 57.12% | 44.42% | 32.07% | 24.08% | 21.75% |
| Average Diluted Shares Outstanding | 57.12% | 44.42% | 32.07% | 24.08% | 21.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |